Finding the right location for Life Sciences companies in Europe is never an easy task when setting up or expanding operations. We have compared and contrasted European countries’ attractiveness for pharma, biotech and medtech companies in terms of business environment, infrastructure, innovation and R&D, and available talent.
What is new in KPMG 2021 edition? You may find articles on EU funding programs, opportunities for contract manufacturers, FDA-regulated pharma manufacturing plants, and the implications of Brexit for obtaining marketing authorizations, among much more.
The last 18 months made establishing a game plan even more complex – but also opened up fresh opportunities. The pandemic forced European countries into rethinking their industrial strategies across Europe – resulting in significant new pools of funding to stimulate economic growth and improve the resilience of critical industries, including life sciences.
Whether for your regional headquarters, shared service center, or manufacturing, warehousing or R&D facility, our report will help you navigate an increasingly complex landscape to reach the right decision.